Marc Ballas

Marc Ballas

Auto-generated profile, based on publicly available information

Marc Ballas

GSK 20 , Collegeville, Pennsylvania

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
SYSapna Yadavilli
Sapna Yadavilli
JWJeremy D. Waight
Jeremy D. Waight
SBSara Brett
Sara Brett
MBMeixia Bi
Meixia Bi
TZTianqian Zhang
Tianqian Zhang
MBMarc Ballas
Marc Ballas
In recent years, there has been considerable interest in mAb-based induction of costimulatory receptor signaling as an approach to combat cancer. However, promising nonclinical data have yet to translate to a meaningful clinical benefit. Inducible T-cell costimulator (ICOS) is a costimulatory receptor important for immune responses. Using a novel clinical-stage anti-ICOS immunoglobulin G4 mAb (feladilimab), which induces but does not deplete ICOS+ T cells and their rodent analogs, we provide an end-to-end evaluation of the antitumor potential of antibody-mediated ICOS costimulation alone and in combination with programmed cell death protein 1 (PD-1) blockade. We demonstrate, consistently, that ICOS is expressed in a range of cancers, and its induction can stimulate growth of antitumor reactive T cells. Furthermore, feladilimab, alone and with a PD-1 inhibitor, induced antitumor activity in mouse and humanized tumor models. In addition to nonclinical evaluation, we present three patient case studies from a first-time-in-human, phase I, open-label, dose-escalation and dose-expansion clinical trial (INDUCE-1; ClinicalTrials.gov: NCT02723955), evaluating feladilimab alone and in combination with pembrolizumab in patients with advanced solid tumors. Preliminary data showing clinical benefit in patients with cancer treated with feladilimab alone or in combination with pembrolizumab was reported previously; with example cases described here. Additional work is needed to further validate the translation to the clinic, which includes identifying select patient populations that will benefit from this therapeutic approach, and randomized data with survival endpoints to illustrate its potential, similar to that shown with CTLA-4 and PD-1 blocking antibodies. Significance: Stimulation of the T-cell activation marker ICOS with the anti-ICOS agonist mAb feladilimab, alone and in combination with PD-1 inhibition, induces antitumor activity across nonclinical models as well as select patients with advanced solid tumors.

22 December 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
DRDanny Rischin
Danny Rischin
AHAaron R. Hansen
Aaron R. Hansen
ECEzra E.W. Cohen
Ezra E.W. Cohen
MTMakoto Tahara
Makoto Tahara
KHKevin Harrington
Kevin Harrington
Christophe Le TourneauChristophe Le Tourneau
Christophe Le Tourneau
Purpose: Feladilimab, an inducible T-cell costimulatory receptor agonist, demonstrated clinical activity in combination with pembrolizumab in a phase I head and neck squamous cell carcinoma (HNSCC) expansion cohort, prompting further evaluation in patients in this setting. Patients and Methods: INDUCE-3 (NCT04128696) was a randomized, double-blind, phase II/III study in patients with first-line PD-L1–positive recurrent and/or metastatic HNSCC. A 2-in-1 adaptive design was implemented, with an option to expand the phase II study into a phase III confirmatory study. Patients were randomized 1:1 to receive feladilimab plus pembrolizumab or placebo plus pembrolizumab, with up to 35 cycles of treatment for approximately 2 years. Primary endpoints were overall survival (OS) and investigator-assessed progression-free survival (PFS). Results: The study enrolled 315 patients. Following the review of unblinded interim data in 140 patients, an Independent Data Monitoring Committee recommended stopping patient accrual based on prespecified criteria. Existing patients discontinued feladilimab or placebo. Pembrolizumab treatment continued until prespecified stopping criteria were met. This study demonstrated no evidence of an effect in favor of feladilimab plus pembrolizumab, with an adjusted HR of 1.51 for OS and 1.40 for PFS (median OS: 44.1 weeks [95% confidence interval (CI), 35.9–not applicable]; median PFS: 10.1 weeks [95% CI, 9.1–15]) versus placebo plus pembrolizumab [median OS: not reached; median PFS: 16 weeks (95% CI, 14.3–26.1)]. The incidence of treatment-related adverse events was higher in the placebo group. Conclusions: This analysis does not support the combination of feladilimab plus pembrolizumab due to a lack of superiority over placebo plus pembrolizumab.